Pfizer applies for authorization of its COVID vaccine in Philippines | Inquirer News

Pfizer applies for authorization of its COVID vaccine in Philippines

/ 09:03 PM December 26, 2020

MANILA, Philippines — American drugmaker Pfizer has submitted its application for Emergency Use Authorization (EUA) of its COVID-19 vaccine in the Philippines, Malacañang said Saturday.

Presidential spokesperson Harry Roque said Food and Drug Administration (FDA) Director-General Rolando Domingo, during a meeting in Malacañang with President Duterte and several Cabinet members, confirmed that Pfizer has filed for EUA last Dec. 23


“It will take FDA 21 days to evaluate and approve the EUA, but vaccination would start as soon as stocks become available,” Roque said in a statement.

Securing an EUA from the Philippines’ regulator will allow a new vaccine to be administered in the country.


The FDA earlier said applicants first need to present the EUA from the regulatory agency in their country of origin before applying in the Philippines. The FDA will use the available data in its evaluation.

Pfizer has already secured an EUA for the US FDA.


For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus, COVID-19, EUA, FDA, NcoV, pandemic, Pfizer, Philippines, vaccine
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.